Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Jerry Call"'
Autor:
Jerry Call, Jonathan Wojtkowiak, Denisse Evans, Pete Knox, Thomas J. Hughes, Maeven Luedke, Sahibjeet Kaur, Carolyn Tordella, Mary Garland, Paul T. Lim, Norman J. Scherzer, Sara Rothschild, Jonathan Trent
Publikováno v:
Cancer Investigation. :1-13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c113cfddd834cd62cae4e723856f5408
https://doi.org/10.1080/07357907.2023.2201629
https://doi.org/10.1080/07357907.2023.2201629
Autor:
Annalisa Astolfi, Anthony Gill, Brian P. Rubin, Denisse Montoya, Sara Rothschild, Jerry Call, Maria A. Pantaleo
Publikováno v:
Pathology. 55(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e9d9db45bfecf85b1027209015cc44f
https://pubmed.ncbi.nlm.nih.gov/35922263
https://pubmed.ncbi.nlm.nih.gov/35922263
Autor:
Yu Wang, Jerry Call
Publikováno v:
Current Cancer Drug Targets. 19:688-697
Targeted treatment has become a major modality in cancer management. Such cancer drugs are generally designed to treat tumors with certain genetic/genomic makeups. Mutational testing prior to prescribing targeted therapy is crucial in identifying who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::198e62bb8287af5f290f92dd217a64d6
https://doi.org/10.2174/1568009619666190326123945
https://doi.org/10.2174/1568009619666190326123945
Autor:
Mary Garland, Sahibjeet Kaur, Maeven Luedke, Sara Rothschild, Jerry Call, Norman J. Scherzer, Denisse Montoya, Jennily Eshak, Pete Knox
Background Due to the low mutational testing rate in patients with Gastrointestinal Stromal Tumors (GIST), The Life Raft Group (LRG), a non-profit organization that provides support, advocacy and conducts research for patients with GIST, analyzed var
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4653106ba37950b38536804a9660d07
https://doi.org/10.21203/rs.3.rs-737437/v1
https://doi.org/10.21203/rs.3.rs-737437/v1
Publikováno v:
Clinical Sarcoma Research, Vol 9, Iss 1, Pp 1-14 (2019)
Background The use of imatinib, sunitinib, and regorafenib has transformed the treatment of advanced GIST. Sunitinib and regorafenib improve progression free-survival in the second (2L) and third (3L) line, respectively, compared with placebo. Howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba7859f33544ac398a6e03fd70ad47f3
http://link.springer.com/article/10.1186/s13569-019-0114-5
http://link.springer.com/article/10.1186/s13569-019-0114-5
Autor:
Matt van de Rijn, Yuexiang Wang, Sebastian Bauer, Anette Duensing, Carol Beadling, Chandrajit P. Raut, Tamas Ordog, Jonathan A. Fletcher, Barbara Dewaele, Maria Debiec-Rychter, Brian P. Rubin, Christopher L. Corless, Thomas Mühlenberg, Janice Patterson, Jerry Call, Michael Heinrich
Publikováno v:
Clinical Sarcoma Research, Vol 9, Iss 1, Pp 1-15 (2019)
Clinical Sarcoma Research
Clinical Sarcoma Research
Background Activating mutations of the receptor tyrosine kinase KIT are early events in the development of most gastrointestinal stromal tumors (GISTs). Although GISTs generally remain dependent on oncogenic KIT during tumor progression, KIT mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c605f88824ad24ce21f3cae7400106e3
http://link.springer.com/article/10.1186/s13569-019-0112-7
http://link.springer.com/article/10.1186/s13569-019-0112-7
Publikováno v:
Clinical Sarcoma Research
Clinical Sarcoma Research, Vol 9, Iss 1, Pp 1-1 (2019)
Clinical Sarcoma Research, Vol 9, Iss 1, Pp 1-1 (2019)
Background The use of imatinib, sunitinib, and regorafenib has transformed the treatment of advanced GIST. Sunitinib and regorafenib improve progression free-survival in the second (2L) and third (3L) line, respectively, compared with placebo. Howeve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7389a445416fc917ebaf3334a2a731
https://doi.org/10.1186/s13569-019-0117-2
https://doi.org/10.1186/s13569-019-0117-2
Autor:
Markku Miettinen, Brian P. Rubin, Sara Rothschild, Christopher L. Corless, Jerry Call, Anthony J. Gill
Publikováno v:
Journal of Clinical Oncology. 38:e23519-e23519
e23519 Background: The Life Raft Group (LRG) identified that succinate dehydrogenase (SDH) deficient GISTs are under-recognized. In the LRG Registry only 30% of KIT/PDGFRA wildtype patients had received the advanced mutational testing (or SDHB staini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4452c0eca0d21884505dbfe98f4d5d2a
https://doi.org/10.1200/jco.2020.38.15_suppl.e23519
https://doi.org/10.1200/jco.2020.38.15_suppl.e23519
Autor:
Michael Heinrich, Jerry Call
Publikováno v:
Journal of Clinical Oncology. 36:e23511-e23511
e23511Background: The use of imatinib (IM), sunitinib (SU), and regorafenib (RE) has transformed the treatment of advanced GIST. SU and RE improve progression free-survival in the second (2L) and t...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18906333ca9bd964c69ad9ab46015f54
https://doi.org/10.1200/jco.2018.36.15_suppl.e23511
https://doi.org/10.1200/jco.2018.36.15_suppl.e23511
Publikováno v:
Journal of Clinical Oncology. 35:e21625-e21625
e21625 Background: Created in 2001, The Lift Raft Group GIST Patient Registry has always put the patient at the heart of its work. Those contributing data are not merely study participants but people in need of help. In 2017, the newest evolution of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e752ca8c63b2ac9e04230314917beb9
https://doi.org/10.1200/jco.2017.35.15_suppl.e21625
https://doi.org/10.1200/jco.2017.35.15_suppl.e21625